HOTAIR and glioblastoma: Further, based upon data from clinical cases of glioblastoma with and without temozolomide resistance, the authors advocated the employment of serum exosomal HOTAIR expression as a diagnostic biomarker for temozolomide sensitivity of glioblastomas (Yuan et al. 2020).